

## Bayer Group Key Data, Fourth Quarter and Full Year 2010

<b>Bayer Group</b> (EUR million)	Q4 2009	<b>Q4 2010</b>	Change in %	FY 2009	<b>FY 2010</b>	Change in %
Sales	7,872	<b>9,012</b>	+14.5	31,168	<b>35,088</b>	+12.6
EBIT	366	<b>51</b>	-86.1	3,006	<b>2,730</b>	-9.2
<i>Special items</i>	<i>(451)</i>	<i>(954)</i>	-	<i>(766)</i>	<i>(1,722)</i>	-
EBIT before special items	817	<b>1,005</b>	+23.0	3,772	<b>4,452</b>	+18.0
EBITDA	1,119	<b>1,510</b>	+34.9	5,815	<b>6,286</b>	+8.1
<i>Special items</i>	<i>(394)</i>	<i>(179)</i>	-	<i>(657)</i>	<i>(815)</i>	-
EBITDA before special items	1,513	<b>1,689</b>	+11.6	6,472	<b>7,101</b>	+9.7
Net income (loss)	153	<b>(145)</b>	-	1,359	<b>1,301</b>	-4.3
Core earnings per share (EUR)	0.90	<b>0.95</b>	+5.6	3.64	<b>4.19</b>	+15.1

<b>Bayer HealthCare</b> (EUR million)	Q4 2009	<b>Q4 2010</b>	Change in %	FY 2009	<b>FY 2010</b>	Change in %
Sales	4,164	<b>4,468</b>	+7.3	15,988	<b>16,913</b>	+5.8
EBIT	463	<b>(129)</b>	-	2,640	<b>1,861</b>	-29.5
<i>Special items</i>	<i>(312)</i>	<i>(901)</i>	-	<i>(372)</i>	<i>(1,169)</i>	-
EBIT before special items	775	<b>772</b>	-0.4	3,012	<b>3,030</b>	+0.6
EBITDA	892	<b>985</b>	+10.4	4,148	<b>4,116</b>	-0.8
<i>Special items</i>	<i>(262)</i>	<i>(153)</i>	-	<i>(320)</i>	<i>(289)</i>	-
EBITDA before special items	1,154	<b>1,138</b>	-1.4	4,468	<b>4,405</b>	-1.4

<b>Bayer CropScience</b> (EUR million)	Q4 2009	<b>Q4 2010</b>	Change in %	FY 2009	<b>FY 2010</b>	Change in %
Sales	1,398	<b>1,653</b>	+18.2	6,510	<b>6,830</b>	+4.9
EBIT	(56)	<b>118</b>	-	798	<b>261</b>	-67.3
<i>Special items</i>	<i>(98)</i>	<i>(26)</i>	-	<i>(219)</i>	<i>(526)</i>	-
EBIT before special items	42	<b>144</b>	-	1,017	<b>787</b>	-22.6
EBITDA	73	<b>244</b>	-	1,311	<b>767</b>	-41.5
<i>Special items</i>	<i>(93)</i>	<i>(26)</i>	-	<i>(197)</i>	<i>(526)</i>	-
EBITDA before special items	166	<b>270</b>	+62.7	1,508	<b>1,293</b>	-14.3

<b>Bayer MaterialScience</b> (EUR million)	Q4 2009	<b>Q4 2010</b>	Change in %	FY 2009	<b>FY 2010</b>	Change in %
Sales	2,016	<b>2,584</b>	+28.2	7,520	<b>10,154</b>	+35.0
EBIT	14	<b>156</b>	-	(266)	<b>780</b>	-
<i>Special items</i>	<i>(45)</i>	<i>0</i>	-	<i>(140)</i>	<i>0</i>	-
EBIT before special items	59	<b>156</b>	-	(126)	<b>780</b>	-
EBITDA	160	<b>297</b>	+85.6	341	<b>1,356</b>	-
<i>Special items</i>	<i>(43)</i>	<i>0</i>	-	<i>(105)</i>	<i>0</i>	-
EBITDA before special items	203	<b>297</b>	+46.3	446	<b>1,356</b>	-

EBITDA, EBITDA before special items and core earnings per share are not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. For the definition of these indicators, see the current annual report at [www.bayer.com](http://www.bayer.com).